Vaxcyte (NASDAQ:PCVX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a note issued to investors on Monday, Benzinga reports. They presently have a $89.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 22.39% from the company’s previous close. A number […]

Levi Strauss & Co. (NYSE:LEVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They currently have a $27.00 price objective on the blue-jean maker’s stock. BTIG Research’s price target would indicate a potential upside of 36.71% from […]

Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued to investors on Tuesday, Benzinga reports. Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” […]

BTIG Research reissued their neutral rating on shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) in a research report report published on Thursday,Benzinga reports. Several other equities analysts also recently weighed in on TBPH. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their target price for the company […]

BTIG Research reissued their buy rating on shares of Atlanticus (NASDAQ:ATLC – Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. They currently have a $179.00 price objective on the credit services provider’s stock. Other analysts have also issued reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of […]

BTIG Research reaffirmed their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a report published on Tuesday morning,Benzinga reports. BTIG Research currently has a $46.00 price objective on the stock. Several other equities research analysts have also issued reports on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating […]

BTIG Research restated their buy rating on shares of Hyperfine (NASDAQ:HYPR – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $2.00 price objective on the stock. A number of other equities research analysts have also recently weighed in on the stock. B. Riley Financial restated a “buy” rating and […]

AC Immune (NASDAQ:ACIU – Get Free Report)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 197.95% from the company’s previous close. ACIU has been the […]